Duchenne Muscular Dystrophy (DMD) Clinical Trials

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the DMD gene, resulting in absence or severe deficiency of the dystrophin protein, which normally provides structural support to muscle fibers. The lack of dystrophin causes progressive muscle fiber breakdown, inflammation, and replacement with fatty and fibrous tissue. Boys typically present ages 2-4 with proximal muscle weakness, causing difficulty running, climbing stairs, and rising from the floor (Gowers sign).

The most common symptoms of Duchenne Muscular Dystrophy include Delayed motor milestones in early childhood, Progressive weakness in legs, hips, and shoulders, Difficulty running, jumping, or climbing stairs, Frequent falling and stumbling, Enlarged, weak calf muscles, among others. Duchenne Muscular Dystrophy affects approximately 1 in 3,500 to 5,000 male births. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Duchenne Muscular Dystrophy from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. DMD research is remarkably active, with multiple exon-skipping therapies approved or in advanced trials, offering hope for slowing or stabilizing disease progression. Two newer oral medicines are FDA approved for DMD regardless of the specific mutation: vamorolone (Agamree), a once-daily corticosteroid liquid approved in October 2023 for patients 2 years and older, and givinostat (Duvyzat), a twice-daily histone deacetylase (HDAC) inhibitor liquid that targets inflammation and muscle loss, approved in March 2024 for patients 6 years and older.

Yes. As of September 2026, Trial Friend lists 8 FDA-approved drugs used to treat Duchenne Muscular Dystrophy: Exondys 51 (eteplirsen), first approved in 2016; Emflaza (deflazacort), first approved in 2017; Vyondys 53 (golodirsen), first approved in 2019; Viltepso (viltolarsen), first approved in 2020; Amondys 45 (casimersen), first approved in 2021; Elevidys (delandistrogene moxeparvovec), first approved in 2023; Agamree (vamorolone), first approved in 2023; and Duvyzat (givinostat), first approved in 2024.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

The FDA is due to decide on Zeleciment rostudirsen by January 21, 2027 and Amondys 45 + Vyondys 53 by February 28, 2027; the FDA calendar page carries the outcome the day it lands.

Duchenne Muscular Dystrophy is caused by variants in the DMD gene. Duchenne and Becker are the same gene; variants that abolish dystrophin cause Duchenne, those leaving partial function cause Becker.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son. The condition affects approximately 1 in 3,500 to 5,000 male births. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Duchenne Muscular Dystrophy looks at the DMD gene. Duchenne and Becker are the same gene; variants that abolish dystrophin cause Duchenne, those leaving partial function cause Becker.

It is X-linked, so it mainly affects boys, and a mother who carries the variant has a 1 in 2 chance of passing it to each son.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Duchenne Muscular Dystrophy clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Duchenne Muscular Dystrophy clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.